Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?